ALGERNON PHARMACEUT. A
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosi… Read more
ALGERNON PHARMACEUT. A (AGW0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ALGERNON PHARMACEUT. A (AGW0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ALGERNON PHARMACEUT. A - Net Assets Trend (None–None)
This chart illustrates how ALGERNON PHARMACEUT. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ALGERNON PHARMACEUT. A (None–None)
The table below shows the annual net assets of ALGERNON PHARMACEUT. A from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ALGERNON PHARMACEUT. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ALGERNON PHARMACEUT. A Competitors by Market Cap
The table below lists competitors of ALGERNON PHARMACEUT. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EnGold Mines Ltd
PINK:GWRRF
|
$573.73K |
|
Intercont (Cayman) Limited Ordinary shares
NASDAQ:NCT
|
$573.76K |
|
Dominion Income Trust 1
AU:DN1
|
$574.34K |
|
DAJIN RESOURCES
F:C2U
|
$574.51K |
|
Veradermics, Incorporated
NYSE:MANE
|
$573.40K |
|
AMBARELLA
BE:A8B
|
$573.12K |
|
Access-Power & Co. Inc
PINK:ACCR
|
$572.84K |
|
BK OF NOVA SCOTIA
MU:BKN
|
$572.80K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALGERNON PHARMACEUT. A's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ALGERNON PHARMACEUT. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ALGERNON PHARMACEUT. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ALGERNON PHARMACEUT. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALGERNON PHARMACEUT. A (AGW0) | €- | N/A | N/A | $573.56K |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |